Articles related to MULTIPLE SCLEROSIS (MS)

The 2024 McDonald criteria continue to emphasize the importance of considering differential diagnoses, including reevaluating the diagnosis periodically over the disease course, even after a diagnosis of MS has been made.

“Fenebrutinib represents the first potential scientific breakthrough for the PPMS community in over a decade.” — Levi Garraway, MD, PhD, Roche Chief Medical Officer

Patterns observed in pediatric-onset MS extend into young adult-onset disease, suggesting continuous rather than dichotomous age effects on health-related quality of life outcomes.

High-dose vitamin D demonstrated a 34% reduced risk of disease activity in both CIS and early RRMS patients, with MRI markers showing particular improvement, though no significant impact on clinical symptoms or disability progression was observed.

“The bottom line to me is that it is just further evidence that you really can modify immune phenotypes [characteristics] with dietary interventions.”

Early use of high-efficacy disease-modifying therapies in pediatric-onset MS patients with minimal disability reduces the risk of progression by 59% compared to no treatment.